NEUP - Wutah dodolan YoY (TTM) Neuphoria Therapeutics

Neuphoria Therapeutics Inc. (NEUP) minimizes financial risks by developing a pipeline of independent CNS drugs. The 12-month year-over-year revenue trend confirms the current momentum, where 0.00 becomes the new value for this metric. Growth is driven by the potential of findelinel in treating PTSD, although full commercialization of the base is expected only after the completion of R&D stages and regulatory approval.
Neuphoria Therapeutics (NEUP) - rincian metrik lan laporan keuangan

Revenue dynamics directly reflect the commercialization stage of Neuphoria Therapeutics Inc. (NEUP) biotechnological developments. This relative year-over-year (12-month) revenue growth indicator calculates the percentage change in total sales over a rolling year. The metric allows for an assessment of business scaling rates while excluding seasonal distortions. For Neuphoria Therapeutics Inc. (NEUP), the lack of growth confirms a dependency on the outcomes of BNC210 trials. A steady upward trend on the chart would signal the acquisition of a strategic partner.